Caplana4.Pdf (225Kb)

Total Page:16

File Type:pdf, Size:1020Kb

Caplana4.Pdf (225Kb) Arthur Caplan Acadia Institute St udy of Bioethics in American So ciety page 1 1 March 2, 1998. Acadia Institute Study of bioethics in American Society. Interview #4 2 with Arthur L. Caplan, Ph.D., Director, Center for Bioethics, Trustee Professor of 3 Bioethics, and Chief, Division of Bioethics, University of Pennsylvania. The interview is 4 being conducted by Dr. Renee C. Fox, and Dr. Carla Messikomer, in Dr. Fox's apartment 5 in Philadelphia. 6 FOX: What was the trajectory of your career at Hastings? You couldn't have gone any 7 further than you went, other than becoming Daniel Callahan himself. So how 8 many years was that all told? 9 CAPLAN: Seven. 10 FOX: Maybe in recounting a little bit your own involvements over those seven years 11 you'll be telling us some things about what was going on at Hastings during that 12 time. 13 CAPLAN: When I say seven, by the way, I am dating that from the time I really was hired as 14 a real staff person. I was there earlier than that as a research assistant, helper, 15 gopher.... 16 FOX: Yes, that's where we left you last time. 17 CAPLAN: I think I told you I was in the second phase of my unethical career. The first one 18 was being a mock medical student. The second was being a post-doc before I was 19 a doc. So I had been there for a year as a post-doc. I'd been there probably in 20 1974 to 1977 as a kind of research assistant type person, very part-time. That's 21 when these things are taking place. Then in 1977-78 I get hired, really put on the 22 faculty. Arthur Caplan Acadia Institute St udy of Bioethics in American So ciety page 2 23 FOX: How did that happen? 24 CAPLAN: Well, it's funny, what really got me hired to was the fact that I seemed to know a 25 lot about genetics. There was a genetics project, an early one at Hastings, had 26 people like John Fletcher, Bob Murray, Marc Lappe, Tabitha Powledge, Alex 27 Capron, on it. I laugh sometimes now when I hear some of the discussion of 28 genetic testing and screening, which acts as if no one ever thought about this. 29 These were early discussions of sickle cell and Tay-Sachs large scale screening 30 and the issues involved, and all the issues were there. Stigmatizing populations, 31 could you get informed consent, did people understand the difference between 32 disease and trait...and on and on. Everything was there. And Hastings ultimately 33 issued a very important document, which I can't remember if I mentioned last 34 time, which was the first ethical guidelines about genetic screening. What was 35 interesting about it wasn't that there were guidelines; it was interesting that it was 36 a Hastings Center group that got into The New En�land Journal and declared 37 guidelines, which was a kind of sociological moment of some interest. It's as if I 38 sat in the room and issued the Art Caplan guidelines, it was like who cares. But 39 clearly Hastings had gotten to the point where a distinguished group would be 40 treated as a serious, blue ribbon panel, or some body of authority and the Journal 41 published their guidelines. That was very interesting for me to watch. I can't say 42 at the time that I was so self-aware of its importance, but I was dimly aware, and it Arthur Caplan Acadia Institute St udy of Bioethics in American So ciety page 3 43 certainly was important looking back on it now. 44 FOX: A very important step in institutionalizing bioethics. 45 CAPLAN: Exactly. It was like Rothman sees Beecher in the 1966 article; the Hastings 46 guidelines was a very important moment in the emergence of non-medically 47 driven bioethics. Here was an interdisciplinary group from a non-medical 48 institution in the leading medical journal publishing on a topic that everybody 49 would have said is something that the geneticists should have done. All that was 50 as interesting; it's as seminal in its way as Beecher's clinical research article 51 because it's saying that all these features are coming together, pay attention to 52 this. Getting baptized almost as a legitimate thing. So that was one of the 53 projects that I helped to staff or do a lot of the scut work. I helped write those 54 guidelines. I would say that Marc Lappe and Tammy Powledge, who were on the 55 staff, did more but I helped them. That was really what got me hired. They knew 56 me pretty well because they had seem me for a couple of years. They had me as a 57 post-doc. I thinkthere was a lot of sentiment. Ruth Macklin would tell you that 58 she wanted to keep me around, and that sort of thing. But it was really the 59 genetics stuff which I seemed to know better, and everybody thought, "Well, 60 genetics is going to have a big future in bioethics." Which it did. Although it's 61 interesting, it dipped. I don't know why it dipped. I have a feeling that there was a 62 little bit of boom and bust, not in the ethics but in the genetics end, that tests were Arthur Caplan Acadia Institute St udy of Bioethics in American So ciety page 4 63 expected to flowafter Tay-Sachs and sickle cell, and didn't. And then it was only 64 the genome mapping project that really got things going in a way that allowed for 65 more disease identification. So I think part of it was that the science stalled, not 66 the ethics. 67 FOX: By and large though, though this is somewhat editorializing, my sense is that 68 bioethicists tended to be more reactive to what developed rather than to go 69 forward and say, "We must continue to work in the genetics area because this is 70 critical." 71 CAPLAN: Some people tried. There were efforts even at that time, in the early '80's, to have 72 a discussion in this genetics group of something hilarious... cloning. We did try. 73 Will Gaylin and I went to every foundation imaginable, one on one. Will knew 74 everybody and we tried to get support for a follow-up project for the genetics 75 group on cloning. And everybody said, "It's science fiction, it's ridiculous, there 76 is no need to do it." So there was no institutional willingness to support 77 something that wasn't real. Plus, to be honest, my impression, was that the 78 scientificcommunity was not willing to tolerate a cloning discussion because it 79 looked too threatening. Remember, subsequent to that there had been a lot of 80 pronouncements about "we will never do germ line engineering," and there were a 81 fair number of pronouncements that we would never do cloning too. But I think 82 these are all defensive, I don't believe any of them for a minute. This idea that Arthur Caplan Acadia Institute St udy of Bioethics in American So ciety page S 83 you wouldn't do germ line genetic engineering, change sperm and eggs, is 84 crazy ... of course you would if you could fix some diseases. You'd absolutely do 85 it. You'd be an idiot not to do it. So what are they talking about? What they 86 mean is we're not going to be eugenecists, we're not going to be Nazis, we're not 87 going to be.... 88 FOX: Where was the recombinant DNA controversy? 89 CAPLAN: That comes in the late 1970's, it's about 1978 to about 1981. And Asilomar must 90 be in there about 1981 , something like that. Did that divert some attention? Yes, 91 and there was one other thing that was going on there too that you'll remember, it 92 was the criminal chromosome fightand the sociobiology and IQ fightingthat was 93 going on at this time. So there were things that were diverting attention away 94 fromthe--let's call it--atoms-for-peace approach to genetics, which was 95 "everything is good and we'll fight diseases, and this will be helpful and will 96 prevent the birth of people with problems." Over to: "Gosh, genetics could be 97 controversial, you might stereotype people." Or maybe it's an attempt to foist 98 eugenic visions on the population, that's what the IQ and the sociobiology debates 99 were about. In fact, a little side note: since we're doing some kind of a history, I 100 was told firmlyby my graduate advisor, ErnstNag el, that I was a fool to spend 101 any time putting together the sociobiology book, which was my first book. Could 102 not take time off from the thesis. I never told him I was doing it, but I did it Arthur Caplan Acadia Institute St udy of Bioethics in American So ciety page 6 103 anyway. It's the biggest selling book I ever wrote! It was like, his intuition is 104 wrong about this! I know, I know, you've got to finish your thesis, I get that. But 105 it was like, this is an opportunity and ifl miss it.. .l know about the biology, I 106 understand the philosophy and this isn't coming back.
Recommended publications
  • Curriculum Vitae
    DANIEL CALLAHAN January 2008 Director International Program The Hastings Center Garrison, N.Y. 10524-5555 (914) 424-4040 BIOGRAPHICAL Born July 19, 1930, Washington, D.C. Married to Sidney deShazo Callahan, Ph.D. (a social psychologist); six children: Mark, Stephen, John, Peter, Sarah and David. Address: Box 260, Hudson House, Ardsley-on- Hudson, New York 10503. Sgt., U.S. Army, 1952-55 (Counterintelligence Corps). EDUCATION B.A. Yale University (1952), English and Psychology major M.A. Georgetown University (1957), Philosophy Ph.D. Harvard University (1965), Philosophy ADMINISTRATIVE, RESEARCH AND EDITORIAL POSITIONS Director, International Programs, The Hastings Center, 1997- Fellow, Institution for Social and Policy Studies, Yale University, 2004- Senior Research Fellow, Department of Philosophy, Yale University, 2004- Senior Lecturer, Harvard Medical School, 1998- Visiting Fellow, Harvard Center for Population and Development Studies, 1996 President and Co-Founder, The Hastings Center, 1969-1996 Staff Associate, The Population Council, 1969-1970 Executive Editor, Commonweal, 1961-1968 PROFESSIONAL ACTIVITIES Special Consultant, Presidential Commission on Population Growth and the American Future (1970-71) Consultant, Ad Hoc Committee on S-hemoglobinopathies, National Academy of Sciences - National Research Council (1972) Selection Committee, Ford-Rockefeller Program in Population Policy (1972-75) Selection Committee, National Book Awards (1975) Council Member, New York Council for the Humanities (1975-79) Member, New York Health Advisory
    [Show full text]
  • International Arbitrage of Controversial Medical Technologies: an Introduction Hiram E
    Case Western Reserve Journal of International Law Volume 35 | Issue 3 2003 International Arbitrage of Controversial Medical Technologies: An Introduction Hiram E. Chodosh Follow this and additional works at: https://scholarlycommons.law.case.edu/jil Part of the International Law Commons Recommended Citation Hiram E. Chodosh, International Arbitrage of Controversial Medical Technologies: An Introduction, 35 Case W. Res. J. Int'l L. 363 (2003) Available at: https://scholarlycommons.law.case.edu/jil/vol35/iss3/3 This Foreword is brought to you for free and open access by the Student Journals at Case Western Reserve University School of Law Scholarly Commons. It has been accepted for inclusion in Case Western Reserve Journal of International Law by an authorized administrator of Case Western Reserve University School of Law Scholarly Commons. INTERNATIONAL ARBITRAGE OF CONTROVERSIAL MEDICAL TECHNOLOGIES: AN INTRODUCTION Hiram E. Chodosht James R. Lisher IPt During the 2002-2003 academic year, the Case Western Reserve University Journal of International Law (the "Journal") and the Frederick K. Cox International Law Center (the "Cox Center") invited a series of experts to explore the difficulties in global regulation of new bio-medical technologies. We entitled the symposium International Arbitrage of Controversial Medical Technologies in order to capture the intersection of two significant developments. First, we endeavored to investigate the rapid proliferation of bio- medical technologies that create deep moral and ethical dilemmas for lawmakers, e.g., genetic engineering, germ line gene therapy, somatic cell gene therapy, untested, risky pharmaceuticals for terrible illnesses, and even biological weapons, and the diverse national approaches to regulating such activity.
    [Show full text]
  • MASSACHUSETTS CATHOLIC CONFERENCE WEST END PLACE 150 Staniford Street, Boston, MA 02114-2511 Phone (617) 367-6060 FAX (617) 367-2767 LEGISLATIVE TESTIMONY
    MASSACHUSETTS CATHOLIC CONFERENCE WEST END PLACE 150 Staniford Street, Boston, MA 02114-2511 Phone (617) 367-6060 FAX (617) 367-2767 LEGISLATIVE TESTIMONY To: Members of the Joint Committee on Public Health From: Daniel Avila., Esq., Associate Director for Policy & Research Re: House 611, “An Act Relative to Reprogrammed Human Skin Cells for Embryonic Stem Cell Research” Date: May 10, 2011 The Massachusetts Catholic Conference (“Conference”) respectfully submits this testimony in support of House Bill 611, “An Act Relative to Reprogrammed Human Skin Cells for Embryonic Stem Cell Research.” HB 611 would amend Massachusetts law governing scientific and medical research involving the use of human stem cells by: 1. prohibiting the creation, experimental use, and destruction of human embryos for research purposes; 2. authorizing research involving the use of adult stem cells obtained from reprogrammed skin cells in a manner that does not harm human life; 3. removing current statutory authorization to individuals to donate their gametes to embryonic stem cell researchers; and 4. preventing the transfer of “abandoned” embryos created through in vitro fertilization for embryonic stem cell research. Since the passage of the Act Enhancing Regenerative Medicine in the Commonwealth (2005 Mass. Acts 27), endorsing research involving the destruction of human embryonic life, remarkable scientific advances have occurred using adult stem cells, such as what the bill refers to as reprogrammed skin cells, that can be obtained without harming human embryos. This past February, the Harvard Crimson newspaper carried a story on the remarkable progress in adult stem cell research that began with this sentence: “Two new studies by Harvard stem cell labs have shown that human induced pluripotent stem cells (iPSCs) are the equivalent of human embryonic stem cells for the purpose of reconstructing certain key types of cells, including neurons.” Shane R.
    [Show full text]
  • Acknowledgments
    ACKNOWLEDGMENTS HE CONSTRUCTION of this account of medical narrative has been enriched by my family and friends and colleagues. Those Twho know something of the history of attention to patients in American medicine and the investigation of the psychosocial issues that complicate their illnesses and their medical care will recognize the influ- ence of the University of Rochester. While I was still at Morehouse, David Satcher lent me The Clinical Approach to the Patient, an influential guide to the patient-physician encounter by Rochesterians William L. Morgan, Jr., and George L. Engel. Once there, I incurred debts that are numerous and great. Throughout the years of my research, my colleagues were un- failingly helpful, subjecting me to little more than a bracing modicum of skepticism about literature's place in understanding medicine. I owe my clinical education especially to Robert L. Berg, Lynn Bickley, Cecile A. Carson, Jules Cohen, Christopher Desch, William R. Drucker, David Goldblatt, William A. Greene, Robert J. Joynt, Rudolph J. Napodano, William L. Morgan, Jr., John Morton, Jr., W. Scott Richardson, John Romano, the late Ernest W. Saward, Olle Jane Sahler, Barbara L. Schuster, Seymour I. Schwartz, and T. Franklin Williams. Craig Hohm, then a third-year resident, was my Aeneas during the first year of clinical observation. Lewis White Beck and Jane Greenlaw were dear and unfail- ing sources of advice and criticism and encouragement. At other institutions Howard Brody, Eric J. Cassell, Rita Charon, Julia E. Connelly, Daniel M. Fox, William Frucht, Robert Kellogg, Loretta Kopelman, Joseph Margolis, John Stone, Carolyn Warner, and William Beatty Warner variously argued about ideas, read chapters, or took me on rounds.
    [Show full text]
  • Bioethics Consultants: Corporate Reliance on a New Field of Consultation
    Health Matrix: The Journal of Law- Medicine Volume 15 Issue 2 Article 9 2005 Bioethics Consultants: Corporate Reliance on a New Field of Consultation Kevin Schadick Follow this and additional works at: https://scholarlycommons.law.case.edu/healthmatrix Part of the Health Law and Policy Commons Recommended Citation Kevin Schadick, Bioethics Consultants: Corporate Reliance on a New Field of Consultation, 15 Health Matrix 433 (2005) Available at: https://scholarlycommons.law.case.edu/healthmatrix/vol15/iss2/9 This Note is brought to you for free and open access by the Student Journals at Case Western Reserve University School of Law Scholarly Commons. It has been accepted for inclusion in Health Matrix: The Journal of Law- Medicine by an authorized administrator of Case Western Reserve University School of Law Scholarly Commons. NOTE BIOETHICS CONSULTANTS: CORPORATE RELIANCE ON A NEW FIELD OF CONSULTATION Kevin Schadickt I. INTRODUCTION The technological advances made within the last several decades have given rise to myriad pharmaceutical and biotechnology compa- nies competing for a stake in the market. The quest for knowledge and market forces driving the advancement of scientific research to develop cures, tests, and therapies for disease creates an inherent problem. Government regulation cannot keep up with the advance- ment of science.1 The result is the potential for a decrease in both the safety of subjects participating in clinical trials and in the availability of federal oversight of ethical research endeavors. Many of the institutional guidelines and regulations governing oversight of scientific research exist under the auspices of the Na- tional Institutes of Health (NIH), 2 the Department of Health and Hu- man Services (DHHS), and the Food and Drug Administration I Kevin Schadick, J.D., Case Western Reserve University School of Law (2005).
    [Show full text]
  • Bioethics Consultation in the Private Sector
    University of Pennsylvania ScholarlyCommons Center for Bioethics Papers Center for Bioethics June 2002 Bioethics Consultation in the Private Sector Baruch Brody Nancy Dubbler Jeff Blustein Arthur L. Caplan University of Pennsylvania, [email protected] Jeffrey P. Kahn See next page for additional authors Follow this and additional works at: https://repository.upenn.edu/bioethics_papers Recommended Citation Brody, B., Dubbler, N., Blustein, J., Caplan, A. L., Kahn, J. P., Kass, N., Lo, B., Moreno, J., Sugarman, J., & Zoloth, L. (2002). Bioethics Consultation in the Private Sector. Retrieved from https://repository.upenn.edu/bioethics_papers/25 © The Hastings Center. Reprinted by permission. This article originally appeared in the Hastings Center Report, Volume 32, Issue 3, June 2002, pages 14-20. http://www.thehastingscenter.org/publications/hcr/hcr.asp NOTE: At the time of publication, author Jonathan D. Moreno was affiliated with the University of Virginia. Currently March 2007, he is a faculty member in the Department of Bioengineering at the University of Pennsylvania. This paper is posted at ScholarlyCommons. https://repository.upenn.edu/bioethics_papers/25 For more information, please contact [email protected]. Bioethics Consultation in the Private Sector Abstract The members of a task force on bioethics consultation report their conclusions. The task force was convened by the American Society for Bioethics and Humanities and the American Society of Law, Medicine, and Ethics, although these groups do not endorse the group's conclusions. Two commentaries follow, and an essay by science reporter Nell Boyce sets the scene. Comments © The Hastings Center. Reprinted by permission. This article originally appeared in the Hastings Center Report, Volume 32, Issue 3, June 2002, pages 14-20.
    [Show full text]
  • 8Th Annual International Estate Planning Institute
    FACULTY BIOGRAPHIES 663 664 Arthur Caplan, PhD Arthur Leonard Caplan, PhD, is the Drs. William F and Virginia Connolly Mitty Professor and the founding director of the Division of Medical Ethics in NYU Langone Medical Center’s Department of Population Health. Prior to coming to NYU Langone, Caplan was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, where he created the Center for Bioethics and the Department of Medical Ethics. Dr. Caplan also taught at the University of Minnesota, where he founded the Center for Biomedical Ethics, the University of Pittsburgh, and Columbia University. He was the Associate Director of the Hastings Center from 1984-1987. Dr. Caplan has served on a number of national and international committees including: the Chair, National Cancer Institute Biobanking Ethics Working Group; the Chair of the Advisory Committee to the United Nations on Human Cloning; the Chair of the Advisory Committee to the Department of Health and Human Services on Blood Safety and Availability; a member of the Presidential Advisory Committee on Gulf War Illnesses; the special advisory committee to the International Olympic Committee on genetics and gene therapy; the ethics committee of the American Society of Gene Therapy; the special advisory panel to the National Institutes of Mental Health on human experimentation on vulnerable subjects and the Wellcome Trust on research in humanitarian crises. He is a member of the board of directors of The Franklin Institute, the Board of Visitors of the Columbia University School of Nursing and the Board of Directors of the American Association of University Professors Foundation.
    [Show full text]
  • Bioethical and Legal Issues in the Time of Covid-19
    11th Annual Pegalis Law Group Health Law Colloquium THE VACCINE: BIOETHICAL AND LEGAL ISSUES IN THE TIME OF COVID-19 DATE Opening remarks will be made by Anthony W. Crowell, Thursday Dean and President; Professor of Law, New York Law School. November 19, 2020 CO-MODERATORS Adam Herbst, Adjunct Professor, NYLS; Co-Director, NYLS TIME Health Law and Patient Safety Project; Lecturer at Columbia 6:00 p.m.–7:30 p.m. EST University’s Mailman School of Public Health Steven E. Pegalis, Adjunct Professor, NYLS; Co-Director, COST NYLS Health Law and Patient Safety Project; Member, Free NYLS Board of Trustees CLE PANELISTS 1.5 credits in Ethics Alison Bateman-House, Assistant Professor, Division of Medical Ethics, Department of Population Health at and Professionalism Grossman School of Medicine, NYU Langone Health (NY transitional and Arthur Caplan, the Drs. William F. and Virginia Connolly nontransitional) Mitty Professor and Founding Head, Division of Medical Ethics at Grossman School of Medicine, NYU Langone New York Law School is Health certified by the New York State Continuing Legal Education Hon. Richard N. Gottfried, New York State Assembly Board as an Accredited Provider (District 75); Chair of the Assembly’s Committee on Health of Continuing Legal Education Alicia Ouellette, President and Dean; Professor of Law, in the State of New York. Albany Law School RSVP: www.nyls.edu/VaccineCLE Zoom link will be sent with written materials 24 hours in advance of the program. WE ARE NEW YORK’S LAW SCHOOL 1 Since 1891 AGENDA 6:00-6:05pm – Opening Remarks – Anthony W. Crowell, Dean and President, New York Law School 6:05-6:10pm – Welcome – Professor Steven E.
    [Show full text]
  • Honoring Arthur L. Caplan
    Journal of Contemporary Health Law & Policy (1985-2015) Volume 16 Issue 1 Article 3 1999 Honoring Arthur L. Caplan Renee C. Fox Follow this and additional works at: https://scholarship.law.edu/jchlp Recommended Citation Renee C. Fox, Honoring Arthur L. Caplan, 16 J. Contemp. Health L. & Pol'y (2000). Available at: https://scholarship.law.edu/jchlp/vol16/iss1/3 This Dedication is brought to you for free and open access by CUA Law Scholarship Repository. It has been accepted for inclusion in Journal of Contemporary Health Law & Policy (1985-2015) by an authorized editor of CUA Law Scholarship Repository. For more information, please contact [email protected]. Honoring Arthur L. Caplan Erratum ix This dedication is available in Journal of Contemporary Health Law & Policy (1985-2015): https://scholarship.law.edu/jchlp/vol16/iss1/3 DEDICATORY ESSAY HONORING ARTHUR L. CAPLAN Renge C. Fox* Contemplating the writing of an introductory piece about Arthur L. Caplan - philosopher of science, bioethicist, public intellectual, and the person to whom this issue of THE JOURNAL OF CONTEMPORARY HEALTH LAW AND POLICY is dedicated - summoned up several per- sonal images of him which have more than a personal meaning: A few years ago, while I was flying across the country on a professional trip, engrossed in reading a good novel and happily elevated 35,000 feet above my usual ground-level activities, I glanced up from my book and saw Arthur Caplan's face before me on a television screen. Via electronic media, he was journeying with my fellow passengers and me, exuberantly discussing bioethical questions about organ transplantation with us, as we sped through the sky.
    [Show full text]
  • Donya S. Khalili 1514 12Th Street NW, Apt
    Donya S. Khalili 1514 12th Street NW, Apt. 4, Washington, D.C. 20005 ⋅ [email protected] ⋅ (202) 321-5438 Education UNIVERSITY OF PENNSYLVANIA LAW SCHOOL, PHILADELPHIA, PA Juris Doctor, May 2008 PERELMAN SCHOOL OF MEDICINE, UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA Masters in Bioethics (M.B.E.), May 2008 YALE UNIVERSITY, NEW HAVEN, CT Bachelor of Arts in Political Science, May 2002 Professional Experience INDIVISIBLE, WASHINGTON, D.C. JAN. 2014 - PRESENT Vice President and Chief Operating Officer • Co-founder of a national nonpartisan nonprofit organization educating and energizing Americans about the vital role of government through communications, engagement, and leadership development. • Develop and implement strategies for communications, research, fundraising, and content. • Manage communication team. • Build coalitions of partners, advisors, artists, and nonprofits to engage and train young people. CORY BOOKER FOR SENATE, PHILADELPHIA, PA 2013- PRESENT Policy Fellow • Crafted domestic policy positions for education, civil rights, criminal justice, gun control, women’s issues, technology, disability rights, judicial nominations, and veterans’ affairs. • Prepared policy papers, memoranda, responses to questionnaires, and talking points. • Represented candidate in constituent meeting concerning mass incarceration policies. • Assisted finance team in organizing sessions with funders and policy leaders in Washington, D.C. INSTITUTE FOR CONSULTATIVE BIOETHICS, PITTSBURGH, PA 2013- PRESENT Bioethics Consultant • Research and write educational materials on bioethical issues for medical practitioners and researchers. SKILLS TO SUCCEED, OLATHE, KS 2012-PRESENT Executive Director, Nonprofit Consultant • Developed and oversaw strategic reorganization of the nonprofit under new mission statement and name. • Designed and launched skills programs for children, youth, and adults with autism spectrum disorder. • Created and presented educational materials about children’s rights to education and other services.
    [Show full text]
  • THRIVE COVID Lecture #1
    MASS VACCINATION: A GLOBAL CALL TO ACTION COVID-19 Virtual Lecture Series March 11th 2021 4-5:30pm EST Arthur Caplan PhD is the Drs. William F. and Virginia Connolly Mitty Professor and founding head of the Division of Medical Ethics at NYU School of Medicine. Previously, he was the Sidney D. Caplan Professor of Bioethics at the University of Pennsylvania Perelman School of Medicine, where he created the Center for Bioethics and the Department of Medical Ethics. He received his PhD from Columbia University, was a USA Today 2001 “Person of the Year”, and one of the ten most influential people in America in biotechnology and the ethics of biotechnology. He is a frequent commentator on bioethics and healthcare and a recipient of numerous prestigious awards including the National Science Foundation/National Science Board for substantial contributions to increasing public understanding of science and engineering in the United States and the Food and Drug Administration’s, Reagan/Udall Foundation, Innovation Award (2019). During the Covid-19 pandemic, Dr. Caplan has directed an advisory group on sports and recreation for the US Conference of Mayors; created a working group on coronavirus vaccine challenge studies; developed an ethical framework for distributing drugs and vaccines for J&J; helped develop rationing policies for NYU LMC and many other health systems; is a member of the WHO advisory committee on Covid, ethics and experimental drugs/vaccines; and helped set policy for WIRB/WCG for research studies. He is an advisor to Moderna and serves on the NCAA Sports and Covid committee. Guthrie (Gus) Birkhead, MD, MPH is Professor Emeritus in the Department of Epidemiology and Biostatistics and Director of the Center for Collaborative HIV Research in Practice and Policy at the School of Public Health, University at Albany.
    [Show full text]
  • 'Complete Regulatory Collapse': Why Complaints About Abortion Doctor Went Nowhere
    3/23/2020 'Complete regulatory collapse': Why complaints about abortion doctor went nowhere Unlimited Access Log In NEWS SPORTS BUSINESS OPINION POLITICS ENTERTAINMENT LIFE FOOD HEALTH REAL ESTATE ADVERTISEMENT 'Complete regulatory collapse': Why complaints about abortion doctor went nowhere by Chelsea Conaboy, Inquirer Staff Writer, Posted: March 21, 2011 AP Cassandra Barger knew something was wrong almost immediately. Kermit Gosnell, the abortion doctor charged in January with eight counts of murder, had begun giving her anesthetic to end a pregnancy. Barger ripped the IV from her arm. Racked by convulsions, she crashed from the exam table to the floor. She would stay there nearly an hour while Gosnell and his staff refused to call 911 or allow her companion to leave the locked clinic for help, according to a lawsuit her lawyer filed. https://www.inquirer.com/philly/news/homepage/20110321__Complete_regulatory_collapse___Why_complaints_about_abortion_d/… © 2020 The Philadelphia Inquirer, LLC 3/23/2020 'Complete regulatory collapse': Why complaints about abortion doctor went nowhere RELATED STORIES Pearl Gosnell's lawyer is tossed by judge, citing conflict of interest; bail-reduction hearing reset Prompted by Gosnell probe, state found troubled clinics Inspections find dangerous conditions at two Phila.-area abortion clinics Barger, 34, a recovering drug addict, had warned Gosnell that she was on methadone when she went to his West Philadelphia clinic April 2, 2005, her filing said. She knew the drug could interact dangerously with certain sedatives. What she could not have known was that Gosnell had a long history of injuring his patients and had let his malpractice insurance lapse nearly a year earlier in violation of state law.
    [Show full text]